Drug Profile
BBDF 101
Alternative Names: Batten-1; BBDF-101Latest Information Update: 10 May 2023
Price :
$50
*
At a glance
- Originator Beyond Batten Disease Foundation
- Developer Beyond Batten Disease Foundation; Theranexus
- Class
- Mechanism of Action Alpha-glucosidase inhibitors; Autophagy stimulants; Glucosylceramide synthase inhibitors; Protein aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Neuronal ceroid lipofuscinosis
Most Recent Events
- 09 May 2023 Theranexus and Beyond Batten Disease Foundation plans a phase III trial for Neuronal ceroid lipofuscinosis in USA and Europe (PO, Capsule)
- 02 Mar 2021 Beyond Batten Disease Foundation (BBDF) enters into an agreement with Actelion Pharmaceuticals to provide Miglustat for the development of BBDF 101 for Batten disease .
- 11 Aug 2020 Theranexus plans a phase I-III trial for Neuronal-ceroid-lipofuscinosis (Batten disease) in 2021, In the US